Haemoclub Announces Multiple babyLance Heel Stick Sales in Italy

PRLog (Press Release) - Oct. 13, 2011 - ROME and ATLANTA – MediPurpose®, a master distributor and manufacturer of medical products, recently announced that Haemoclub International SLR has closed several medical device sales for the babyLance® infant heel incision devices in the Italian healthcare market.

“We are excited about Haemoclub’s potential with our heel stick in the Italian medical product space,” said MediPurpose President and COO Randy Prather. “Along with their successes in initiating in-services with numerous hospitals and clinics, they’ve also worked actively to assist with in-country registration.”

According to Haemoclub International’s Patrick Vito, MediPurpose blood collection devices have been generating significant attention at several hospitals and healthcare facilities in Italy where nurses and clinicians have been testing the medical products.

In particular, Vito is confident that both models of babyLance—the Preemie (BLP) and the Newborn (BLN)—and MediPurpose’s SurgiLance® SLN100 are positioned to become highly competitive players in the Italian medical product market.
   
Designed expressly for infants, babyLance is an ideal device for drawing blood from the heels of infants. Likewise, the SurgiLance SLN100’s needle—with 1.0mm depth of penetration—is an appropriate complement for pediatric fingersticks.

Italy has the third-largest medical device market in Europe, according to Espicom Business Intelligence. The Italian market for medical equipment and supplies is valued at US $8.0 billion, which is equal to US $133 per capita.

According to Prather, who oversees the company’s global blood collection and analytics division, the timing is ripe for Italian and other European healthcare facilities to adopt these products.

“Changes in international regulatory requirements now mandate the use of single-use fingersticks,” said Prather. “This is very similar to the requirements of the 2001 Safety Needle Act in the United States, and we anticipate the market will continue to expand as a result.” 

Both babyLance and SurgiLance have received 510(k) clearances from the U.S. Food and Drug Administration (FDA). The FDA clearances demonstrate MediPurpose’s commitment to ensuring the highest standards of safety for both patient and healthcare provider.

More information about babyLance—including demonstration videos and no-cost product sample requests—is available at www.medipurpose.com/babylance/.

# # #

About MediPurpose
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.

Known for its popular babyLance® heel incision device, SurgiLance® safety lancet and MediPlus™ advanced wound care products, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and medical product distributors.

MediPurpose's Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.

For more information about MediPurpose’s medical products and solutions for inventors, innovators, manufacturers and distributors, please visit http://www.medipurpose.com .